Long-Acting Naltrexone Implant: How It Works, Uses, Duration, Safety and Treatment Planning
No opioid-free waiting window before starting treatment at DeBinge When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
A long-acting naltrexone implant is a sustained-release formulation designed to deliver the opioid antagonist naltrexone over an extended period without requiring a tablet every day. Naltrexone blocks opioid receptors rather than activating them. It has established roles in treatment for opioid use disorder and alcohol use disorder, but the strength of evidence, regulatory status and practical considerations differ substantially between oral, injectable and implant formulations.
For people considering an implant, the central questions are not simply “Does naltrexone work?” or “How long does an implant last?” The clinically important questions include which formulation has actually been studied, whether the person is safely prepared for naltrexone, what other treatment options are available, how overdose risk will be managed, what behavioural treatment accompanies medication and what regulatory standards apply to the specific product.
Naltrexone implant formulations are not FDA-approved for clinical use in the United States. FDA-approved U.S. naltrexone options include appropriate oral naltrexone formulations and extended-release injectable naltrexone. DeBinge implant-based treatment is provided in Nassau, The Bahamas, not in Miami, Atlanta, Charlotte or any other U.S. city. Patients comparing local U.S. care with international implant treatment can read the detailed guide to where long-acting naltrexone implant treatment is available.
Long-Acting Naltrexone Explained
- What is a naltrexone implant?
- How naltrexone works
- Antagonists, agonists and partial agonists
- Oral vs injection vs implant
- Explore the knowledge library
- Opioid use disorder
- Alcohol use disorder
- Preparation before treatment
- Implant procedure
- Adherence and counselling
- Safety and overdose considerations
- FDA status and U.S. availability
- What the evidence actually shows
- Treatment selection
- Treatment in The Bahamas
- Pre-treatment questions quiz
- Frequently asked questions
Explore the Long-Acting Naltrexone Knowledge Library
This cornerstone guide explains the overall science, safety, evidence and treatment-planning issues. The resources below go deeper into the questions that often require their own discussion, including opioid and alcohol treatment, U.S. availability, formulation comparisons, provider selection, privacy and continuing care.
Where Implant Treatment Is Available
Understand the difference between FDA-approved naltrexone care available in the United States and implant-based treatment provided in Nassau, including the extra questions created by international care.
Explore U.S. availability and Bahamas treatment →Naltrexone After Opioid Dependence
Go deeper into DeBinge’s medically supervised opioid-to-naltrexone transition, including the buprenorphine bridge, implantation around day 4 or 5 during the taper, the planned overlap through days 5–7, fentanyl considerations, overdose safety and the evidence for sustained-release naltrexone.
Read the opioid-treatment guide →Naltrexone and Alcohol Recovery
Review what is known about naltrexone for alcohol use disorder, how withdrawal treatment differs from relapse-prevention medication, and where implant-specific evidence remains more limited.
Explore the alcohol-use-disorder evidence →Oral Naltrexone, Vivitrol and Implant Treatment
Compare dosing frequency, adherence, initiation requirements, evidence, regulation and cost without treating a single injection price as equivalent to a complete international treatment programme.
Compare the three naltrexone approaches →How to Compare Implant Programs
Use a transparent framework to ask about clinician qualifications, the exact formulation, product-specific evidence, duration, regulation, preparation, costs, emergencies and aftercare.
See the treatment-program comparison framework →Private and Confidential Treatment
Learn the difference between privacy, confidentiality, discretion and anonymity, including questions about records, family communication, counselling confidentiality and international care.
Read the confidential-treatment guide →Relapse Prevention After Detox or Rehab
See how medication fits into medically supervised continuing care alongside counselling, mental-health treatment, structure, naloxone, family involvement and early response if substance use returns.
Explore medically supervised continuing treatment →About the DeBinge Treatment Setting
For patients considering travel, the clinic page explains the Nassau treatment environment and helps distinguish the actual treatment location from DeBinge’s U.S.-focused educational pages.
View the Nassau clinic information →What Is a Long-Acting Naltrexone Implant?
Naltrexone is a medication that binds strongly to opioid receptors without activating them. A naltrexone implant places a sustained-release preparation beneath the skin so that naltrexone is gradually released into the body over time. The objective is to maintain medication exposure for substantially longer than one oral dose and reduce the number of adherence decisions required from the patient.
The term “naltrexone implant” does not describe one universal product. Different implant formulations have used different doses, polymers, numbers of pellets, release characteristics and intended durations. Some are biodegradable; other designs may differ in whether or how they can be removed. Evidence from one implant therefore cannot automatically be applied to another implant simply because both contain naltrexone.
Published research has investigated implant formulations lasting from weeks to several months. The 2025 Cochrane review of sustained-release naltrexone included seven randomized studies using subcutaneous implants as well as studies of extended-release injections. Several implant trials evaluated durations around two to six months. Newer investigational technologies are attempting to extend drug release further, but early-phase products should not be treated as equivalent to established formulations.
How Does Naltrexone Work?
Naltrexone is an opioid receptor antagonist, with clinically important activity at mu-opioid receptors. Opioids such as heroin, fentanyl, oxycodone and morphine produce many of their effects by activating these receptors. When adequate naltrexone concentrations are present, naltrexone occupies receptors and can block or substantially reduce the effects of subsequently used opioids.
Unlike methadone or buprenorphine, naltrexone does not activate opioid receptors to provide opioid agonist effects. It does not create the same opioid reinforcement and generally does not produce opioid physical dependence. That difference is also why a person who is currently physically dependent on opioids must be carefully transitioned before receiving naltrexone: administering an antagonist while opioids are still maintaining physical dependence can abruptly displace opioid activity and precipitate severe withdrawal.
Opioid receptor blockade is powerful, but not absolute
Naltrexone should not be described as an impenetrable chemical shield. FDA prescribing information for extended-release injectable naltrexone warns that opioid blockade is surmountable. Taking very large quantities of opioids in an attempt to overpower the antagonist can cause life-threatening or fatal opioid poisoning. A person should never be encouraged to “test” whether naltrexone is still working.
The biological role of naltrexone in alcohol use disorder is different. Alcohol does not simply bind to opioid receptors in the way heroin does. Instead, the endogenous opioid system forms part of alcohol’s reward and reinforcement pathways. Naltrexone can reduce the reinforcing value of alcohol and, for some patients, reduce heavy drinking or the urge to continue drinking once alcohol use begins. Response varies substantially between individuals.
Antagonist vs Partial Agonist vs Full Agonist Treatment
The major medications used for opioid use disorder do not all work in the same way. SAMHSA and ASAM distinguish between full opioid agonist, partial opioid agonist and antagonist treatment. Understanding these differences is important because naltrexone is not simply a longer-lasting version of buprenorphine or methadone.
Full agonist
Methadone activates mu-opioid receptors. When appropriately prescribed for OUD, it can suppress withdrawal and cravings and reduce illicit opioid use.
Partial agonist
Buprenorphine activates the same receptor but has a ceiling to some opioid effects. It can suppress withdrawal and cravings while producing less receptor activation than a full agonist.
Antagonist
Naltrexone occupies opioid receptors without activating them. It requires successful opioid withdrawal before initiation in a physically dependent patient.
None of these mechanisms makes one medication universally appropriate for every patient. Methadone and buprenorphine have especially strong evidence for reducing opioid-related mortality during treatment. Naltrexone offers a non-agonist option that may fit people who prefer an opioid-free antagonist approach and can complete the transition onto it. Medication selection should consider current opioid use, previous treatment, withdrawal risk, adherence, access, patient preference, co-occurring conditions and overdose risk.
Oral Naltrexone vs Extended-Release Injection vs Implant
The active drug may be naltrexone, but formulation changes how treatment is delivered, how adherence works, how long exposure continues and what procedure-related risks exist.
| Formulation | Typical concept | Main adherence consideration | U.S. regulatory position |
|---|---|---|---|
| Oral naltrexone | Tablet taken according to the prescribed schedule. | The person must continue taking medication consistently. Missed or deliberately stopped doses can quickly reduce coverage. | FDA-approved oral naltrexone formulations are available in the United States; indications depend on the product labeling. |
| Extended-release injectable naltrexone | Intramuscular depot injection providing approximately one month of exposure. | Removes daily pill-taking but requires repeated monthly administration. | FDA-approved extended-release injectable naltrexone is available for alcohol dependence and prevention of relapse to opioid dependence after detoxification. |
| Naltrexone implant | Sustained-release medication inserted subcutaneously, with duration dependent on the specific formulation. | Can substantially reduce day-to-day adherence decisions during the period of drug release. | No naltrexone implant formulation is FDA-approved for clinical use in the United States. |
Cost comparisons also need context. The price of tablets, one monthly injection and a broader international treatment programme do not represent the same bundle of care. For a deeper comparison of dosing, adherence, evidence, regulation and financial considerations, see the DeBinge guide comparing oral naltrexone, Vivitrol and sustained-release implant treatment.
The principal theoretical adherence advantage of an implant is straightforward: medication exposure does not depend on remembering or choosing to swallow a tablet every morning. However, adherence to medication is only one part of treatment. An implant cannot ensure counselling attendance, eliminate exposure to triggers, change relationships or environments, treat every psychiatric condition or guarantee that a person will not attempt substance use.
Long-Acting Naltrexone for Opioid Use Disorder
For opioid use disorder, the pharmacological aim of naltrexone is to maintain opioid receptor antagonism after a medically supervised transition. At DeBinge, buprenorphine is used to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. During approximately days 5–7, buprenorphine continues to clear as the implant gradually releases naltrexone, creating a controlled pharmacological handover. While adequate antagonist activity is present, heroin and other opioid agonists may produce substantially reduced rewarding, sedating and euphoric effects.
This can change the consequences of an impulsive decision to use opioids, but it should not be described as guaranteed relapse prevention. A person may discontinue treatment, use other substances, attempt to overcome blockade or return to opioid use after antagonist exposure falls. Recovery therefore requires more than receptor blockade.
A major challenge with antagonist treatment occurs before treatment begins. Unlike methadone or buprenorphine, naltrexone cannot normally be started while significant opioid physical dependence remains. Completing the transition to an opioid-free state can be difficult, particularly for people using fentanyl, methadone, buprenorphine or other longer-acting opioids.
The 2025 Cochrane review of sustained-release naltrexone included 22 randomized studies and 3,416 participants. It found that results depended heavily on what sustained-release naltrexone was compared against. Compared with treatment as usual, sustained-release naltrexone reduced in-treatment illicit opioid use. Compared with oral naltrexone, it may reduce illicit opioid use, but evidence for several other outcomes remained uncertain. When compared with opioid agonist treatment, sustained-release naltrexone did not demonstrate a simple overall superiority and may have resulted in slightly more illicit opioid use in the available comparison. Much of the evidence was low or moderate certainty.
People weighing antagonist treatment after heroin, fentanyl or other opioid dependence can continue with the dedicated guide to opioid use disorder, preparation and long-acting naltrexone, which expands on medication choices, induction risk and relapse-prevention planning.
Naltrexone and Alcohol Use Disorder
Naltrexone is one of the best-established medication options for alcohol use disorder. Evidence is strongest for established oral naltrexone and extended-release injectable naltrexone rather than for implant formulations as a class.
A major 2023 systematic review and meta-analysis covering 118 clinical trials found moderate-strength evidence supporting oral naltrexone for reducing return to heavy drinking. Extended-release injectable naltrexone has also been studied in randomized trials. Importantly, these findings cannot automatically be transferred to every implant formulation.
Research specifically evaluating implants for alcohol use disorder has historically been much more limited. More recent randomized research is emerging, including a 2026 publication describing a placebo-controlled implant study in 70 participants that reported a difference in percentage of heavy-drinking days over 24 weeks. This is scientifically relevant but remains evidence for a particular investigated formulation and study population rather than proof that all naltrexone implants will produce the same result.
Naltrexone also does not create an aversive alcohol reaction in the way disulfiram is intended to. Some people continue to drink while taking naltrexone. The treatment goal may be abstinence, reduced heavy drinking or another clinically agreed target depending on the individual, medical risks and treatment plan.
Because the evidence base for alcohol treatment differs by formulation, the dedicated alcohol-use-disorder and naltrexone implant evidence guide separates established evidence for oral and injectable naltrexone from the smaller implant-specific literature.
Preparation Before Naltrexone: Why Opioid-Free Status Matters
Preparation is one of the most medically important parts of naltrexone treatment. A person who is physically dependent on opioids can experience abrupt and potentially severe precipitated withdrawal if naltrexone is introduced too soon.
Current FDA labeling for extended-release injectable naltrexone recommends an opioid-free period of at least 7–10 days for patients previously dependent on short-acting opioids. The same labeling warns that people transitioning from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as two weeks. These numbers are useful reference points for the FDA-approved injectable product, but they should not be converted into a universal implant detox schedule.
Fentanyl complicates fixed timelines
Modern illicit opioid exposure can be unpredictable. Fentanyl may be used repeatedly, mixed with other substances or accompanied by medications with longer elimination characteristics. A person’s history may also be incomplete because street drugs do not always contain what the user believes they contain.
For that reason, readiness for antagonist treatment should be established clinically rather than by counting a fixed number of days. Assessment may include substance-use history, withdrawal symptoms, medication history, examination, toxicology testing and, where clinically appropriate, other procedures used to evaluate whether naltrexone can be started safely.
If there is current opioid dependence, preparation should be planned by clinicians experienced in opioid withdrawal and antagonist induction. Severe precipitated withdrawal can require hospital-level care.
This principle also applies to people seeking naltrexone for alcohol use disorder. Recent opioid use still matters because a person may be physically opioid-dependent even when alcohol is the primary reason for treatment.
How Is a Naltrexone Implant Placed?
The exact procedure depends on the product and clinical protocol. In general, implant formulations used in published research have been placed into subcutaneous tissue through a small incision, usually under local anaesthetic. The medication-containing implant or pellets are positioned beneath the skin and the wound is then closed and dressed.
This should be treated as a medical procedure rather than as a simple medication administration. Before placement, clinicians should evaluate suitability for naltrexone itself as well as suitability for the procedure.
Procedure-related considerations
- pain and tenderness;
- bleeding or bruising;
- infection;
- scarring;
- wound separation or delayed healing;
- local inflammatory or foreign-body reactions;
- implant extrusion, movement or need for intervention in some circumstances.
Medication-related considerations
- nausea or gastrointestinal effects;
- headache or fatigue;
- liver-related considerations;
- interactions with future opioid pain treatment;
- precipitated withdrawal if opioids have not been adequately cleared;
- overdose risk associated with reduced opioid tolerance and attempts to override blockade.
Not all sustained-release implants have the same construction or removability. Some newer products are designed to biodegrade. Anyone considering treatment should ask what material is being implanted, how long it has been studied, whether it can be removed, what happens if surgery or opioid analgesia becomes necessary and what follow-up is provided for local complications.
Adherence, Counselling and Behavioural Treatment
One reason sustained-release naltrexone has been studied is the long-recognised adherence problem with oral antagonist treatment. A tablet is effective only when it is actually taken. When motivation fluctuates, cravings increase or a person plans to use opioids, stopping oral naltrexone can become part of the return-to-use process.
A long-acting formulation makes discontinuing medication more difficult during its active period. That is a meaningful pharmacological difference, but it does not mean that behavioural treatment becomes unnecessary.
SAMHSA describes naltrexone as one component of a comprehensive treatment plan. FDA labeling for extended-release injectable naltrexone similarly states that treatment should be part of a comprehensive program including psychosocial support. Many randomized studies of sustained-release naltrexone also included counselling alongside medication.
Counselling and recovery work can address areas that receptor blockade cannot: triggers, trauma, emotional regulation, relationships, stress, sleep, employment, boredom, co-occurring psychiatric symptoms, social networks and planning for what happens when long-acting medication eventually wears off.
For patients leaving detox or rehab, medication is only one part of the next phase. The DeBinge guide to medically supervised continuing care and relapse prevention explains how reassessment, medication, counselling, mental-health care, naloxone and early response to renewed substance use can work together.
Naltrexone, Opioid Tolerance and Overdose Risk
Naltrexone can reduce or block opioid effects while sufficient antagonist activity is present, but describing it as guaranteed overdose prevention would be medically inappropriate.
There are several distinct risks that patients and families should understand.
1. Opioid tolerance falls during abstinence
After detoxification and a period without opioids, tolerance can decline. A dose that was previously tolerated may therefore become dangerous if opioid use resumes later. This applies after many forms of abstinence, not only naltrexone treatment.
2. Blockade can eventually weaken
Every sustained-release formulation has a finite period of exposure. As medication concentrations decline, the degree of blockade also changes. A person cannot safely assume that an old opioid dose is tolerable simply because it produced little effect earlier during treatment.
3. Trying to overpower blockade is dangerous
FDA prescribing information for extended-release injectable naltrexone specifically warns that naltrexone’s competitive blockade can be overcome by sufficiently high opioid concentrations. Attempting this can produce fatal opioid intoxication. Similar pharmacological caution is relevant when discussing other sustained-release naltrexone formulations.
4. Naloxone should remain part of opioid safety planning
People with a history of opioid use disorder, and their families or close contacts, should discuss access to naloxone or another locally available opioid-reversal medication with a clinician. They should know how to recognise slowed or stopped breathing, unresponsiveness and other signs of overdose and how to activate emergency services.
5. Emergency pain treatment requires planning
Naltrexone can complicate opioid analgesia. Patients should tell surgeons, dentists, emergency clinicians and other healthcare professionals that they are receiving long-acting naltrexone. Non-opioid and regional approaches may be considered where appropriate, while emergency opioid management may require specialised monitoring.
Families should not interpret an implant as a reason to remove naloxone, reduce supervision during high-risk periods or ignore a possible overdose. If a person is unresponsive or breathing abnormally, treat it as an emergency.
Is a Naltrexone Implant FDA-Approved in the United States?
This distinction matters because “naltrexone is FDA-approved” and “a naltrexone implant is FDA-approved” are not interchangeable statements.
The United States has FDA-approved naltrexone options, including appropriate oral formulations and extended-release injectable naltrexone. The FDA currently lists intramuscular extended-release naltrexone among approved medications for opioid use disorder. Extended-release injectable naltrexone is also approved for alcohol dependence under its product labeling.
An implant that contains the same active drug does not inherit FDA approval from tablets or injections. Different delivery systems require evaluation of manufacturing, dose release, pharmacokinetics, safety, procedure-related risks and clinical outcomes.
People in the United States considering an implant should therefore distinguish between:
- evidence supporting the molecule naltrexone;
- evidence supporting oral or injectable naltrexone;
- evidence supporting a particular sustained-release implant formulation;
- regulatory authorization in the country where treatment is actually performed.
For more detail, see U.S. availability and treatment in The Bahamas.
What Does the Evidence on Sustained-Release Naltrexone Actually Show?
The most responsible interpretation is that sustained-release naltrexone has clinically relevant evidence, particularly in opioid dependence, but the evidence base is heterogeneous. It includes different injections, different implants, different countries, different comparators and different psychosocial treatments.
2025 Cochrane review
The updated Cochrane review published in May 2025 evaluated 22 randomized controlled trials involving 3,416 participants. Seven studies used subcutaneous naltrexone implants, 14 used intramuscular depot injections and one did not specify route. The evidence search was current to December 2023.
The review concluded that sustained-release naltrexone reduced illicit opioid use compared with treatment as usual. Compared with oral naltrexone, sustained-release treatment may reduce illicit opioid use, although confidence in several other outcomes was limited. Comparisons with opioid agonist treatment produced more cautious findings: sustained-release naltrexone probably resulted in slightly more in-treatment illicit opioid use in the available comparison, while effects on retention and acceptability remained uncertain.
The review also emphasised methodological limitations, small study numbers for several comparisons, lack of long-term outcome data and inadequate evidence specifically involving contemporary synthetic-opioid populations. That limitation is particularly relevant in the fentanyl era.
Randomized implant-versus-oral studies
A 2009 Australian randomized double-blind study involving 70 heroin-dependent participants compared a sustained-release implant with daily oral naltrexone. Implant recipients maintained therapeutic blood concentrations more consistently during early follow-up and returned to regular heroin use less often than the oral-treatment group during the six-month study. This study evaluated one specific implant formulation and cannot establish the performance of every implant.
A larger 2012 randomized trial in Russia assigned 306 recently detoxified opioid-dependent participants to a naltrexone implant, oral naltrexone or placebo while all groups received counselling. At six months, more participants receiving the implant remained in treatment without relapse than participants receiving oral naltrexone or placebo. Again, the findings apply to the investigated formulation and context.
Comparison with buprenorphine or methadone requires caution
Modern clinical decision-making should not frame antagonist therapy as automatically superior to opioid agonist therapy. Methadone and buprenorphine have extensive evidence supporting treatment retention and mortality reduction. Naltrexone has a different mechanism and requires successful opioid withdrawal before induction. The correct comparison therefore includes not only what happens after medication begins, but whether a person can safely and successfully start the treatment at all.
Alcohol evidence is strongest for established formulations
For alcohol use disorder, oral naltrexone has a substantial evidence base and extended-release injectable naltrexone also has randomized-trial evidence. Implant-specific alcohol research is developing but remains much smaller. Any clinic discussing implant treatment for AUD should make that distinction clear rather than presenting the broad evidence for naltrexone as if every study involved an implant.
Who Should Consider Long-Acting Naltrexone?
A webpage cannot determine whether a naltrexone implant, monthly injection, oral naltrexone, buprenorphine, methadone or another treatment is appropriate for a particular person. That decision requires an individual medical assessment.
Questions commonly relevant to treatment selection include:
Substance and medication history
- Which opioids, alcohol or other substances are currently being used?
- Is physical opioid dependence present?
- Has the person used fentanyl, methadone or buprenorphine?
- What treatments have been tried previously?
Medical considerations
- Are there liver, surgical or wound-healing concerns?
- Is opioid pain treatment likely to be required?
- What prescription and non-prescription medications are being used?
- Are there psychiatric or other medical conditions requiring coordinated care?
Treatment goals
- Is the goal abstinence, reduction in heavy drinking, opioid blockade or another outcome?
- Does the person specifically prefer a non-agonist treatment?
- How important is avoiding daily medication?
Recovery structure
- What counselling will accompany medication?
- Who will provide follow-up?
- Is naloxone available where opioid exposure remains possible?
- What is the plan when long-acting medication eventually wears off?
Choosing a provider is a separate decision from choosing naltrexone itself. Patients can use the 15-question implant-program comparison framework to examine clinician qualifications, the exact formulation, published evidence, regulatory status, preparation, costs, emergencies and aftercare without relying on claims that any one provider is universally “best.”
Naltrexone Implant Treatment Outside the United States
Because naltrexone implants are not FDA-approved for clinical use in the United States, a U.S. resident considering implant treatment abroad should understand both the medical treatment and the practical implications of receiving care in another jurisdiction.
DeBinge implant-based treatment takes place in Nassau, The Bahamas. DeBinge does not operate implant clinics in Miami, Atlanta, Charlotte or elsewhere in the United States. U.S.-focused DeBinge pages are intended to provide information for residents researching treatment and travel, not to imply that the implant procedure is performed in those cities.
Travel planning should include more than the flight
Before international treatment, patients should understand who will conduct the medical assessment, where opioid withdrawal or alcohol-related medical stabilization will occur if needed, which product is being considered, what happens if treatment is not clinically appropriate and who provides follow-up after returning home.
Other practical questions include wound care, travel after the procedure, medications to carry, communication with the patient’s usual doctor, emergency information about naltrexone blockade and continuity of counselling.
International care also raises practical questions that do not arise from the medication alone. Patients concerned about records, family communication or professional discretion can review the guide to private and confidential addiction treatment. Those evaluating the physical treatment setting can separately review DeBinge’s Nassau clinic information before deciding whether travel is appropriate.
Considering treatment in The Bahamas?
A consultation should be used to understand the treatment, preparation requirements, alternatives, risks and whether further medical assessment is appropriate. It should not be treated as a guarantee that an implant will be recommended.
Where Implant Treatment Is Available Compare Treatment QuestionsWhat Questions Should You Ask Before Considering Long-Acting Naltrexone?
This nine-question tool does not diagnose a substance use disorder or recommend an implant. It identifies topics that may deserve more discussion with a qualified clinician before a treatment decision is made.
Your responses are processed only inside your browser and are not submitted to DeBinge.
Your Results
Your answers suggest that the following subjects may deserve particular attention when you speak with a clinician. They do not indicate whether an implant is suitable for you.
Questions to Ask a Clinician or Implant Provider
- What exact implant formulation are you proposing? Ask for the manufacturer, dose, delivery technology and expected pharmacokinetic duration.
- What published evidence relates specifically to this formulation? Evidence for oral naltrexone, Vivitrol or another implant is not automatically evidence for the product being proposed.
- Is this product approved by the regulator in the country where treatment occurs?
- How will you determine that I am safely opioid-free? This is especially important after fentanyl, methadone, buprenorphine or uncertain street-drug exposure.
- What alternatives should I consider? For OUD this may include buprenorphine, methadone and FDA-approved extended-release naltrexone.
- What happens if I need surgery or strong pain relief while naltrexone is active?
- What local complications have been reported with this implant and how are they managed?
- What counselling and follow-up are included?
- What is the overdose-safety plan? Ask specifically about reduced tolerance, naloxone and the period when blockade begins to decline.
- What happens when the implant reaches the end of its effective period? Long-term recovery planning should begin before medication coverage ends.
Long-Acting Naltrexone Implant FAQ
1. What is a naltrexone implant?
A naltrexone implant is a sustained-release formulation placed beneath the skin to release naltrexone over an extended period. Different implants use different doses and delivery technologies, so duration and evidence must be assessed product by product.
2. Is a naltrexone implant FDA-approved?
No naltrexone implant formulation is FDA-approved for clinical use in the United States. U.S. FDA-approved naltrexone options include appropriate oral formulations and extended-release injectable naltrexone.
3. How long does a naltrexone implant last?
There is no single duration for every implant. Published research has examined products with effects lasting from weeks to several months, including approximately six-month formulations. Duration depends on the exact product, dose, release characteristics and individual pharmacokinetics.
4. Does a naltrexone implant stop cravings?
Naltrexone may reduce cravings for some people, but responses vary. It should not be described as eliminating cravings. Psychological, environmental and learned triggers can continue even while opioid receptors are blocked.
5. Can someone use heroin or fentanyl while taking naltrexone?
Using opioids while adequate naltrexone activity is present may produce reduced effects, but attempting to overcome blockade with larger quantities is extremely dangerous. FDA labeling for extended-release naltrexone warns that blockade is surmountable and attempts to overpower it can cause fatal overdose.
6. Does naltrexone prevent opioid overdose?
Naltrexone can block or reduce opioid effects while sufficient antagonist concentrations are present, but it does not guarantee overdose prevention. Reduced tolerance, attempts to override blockade and opioid use as medication levels decline can all create serious risk. Naloxone and overdose education remain important.
7. Can naltrexone be started immediately after stopping opioids?
Not when significant opioid physical dependence remains. Starting naltrexone too soon can cause precipitated withdrawal. The required preparation varies with the opioid used, duration of exposure, physiology and clinical findings. Fentanyl, buprenorphine and methadone can make fixed schedules particularly unreliable.
8. Is naltrexone the same as naloxone?
No. Both are opioid antagonists, but they are used differently. Naloxone is a short-acting emergency medication used to reverse opioid overdose. Naltrexone is used as ongoing treatment for alcohol or opioid-related disorders in appropriate patients.
9. Is naltrexone the same as buprenorphine?
No. Naltrexone is an opioid antagonist and does not activate the opioid receptor. Buprenorphine is a partial opioid agonist. Buprenorphine can be started as part of treatment while managing opioid dependence; naltrexone generally requires the patient to become opioid-free first.
10. Can naltrexone implants be used for alcohol use disorder?
Naltrexone itself has substantial evidence for alcohol use disorder, particularly oral and extended-release injectable formulations. Implant-specific evidence is smaller and formulation-dependent. Anyone considering an implant for AUD should ask what evidence supports that exact product.
11. Does an implant replace counselling?
No. Medication can address biological aspects of addiction and adherence, but counselling and behavioural treatment address triggers, coping skills, relationships, mental health, routines and long-term recovery planning. Major clinical guidance treats medication and psychosocial support as complementary.
12. Where does DeBinge provide implant-based treatment?
DeBinge implant-based treatment is provided in Nassau, The Bahamas. DeBinge does not operate naltrexone implant clinics in Miami, Atlanta, Charlotte or elsewhere in the United States.
Scientific and Clinical Sources
This guide is based on current public-health guidance, regulatory information and peer-reviewed research. The evidence should be interpreted according to the formulation studied rather than assuming that every sustained-release naltrexone product is clinically interchangeable.
SAMHSA
Substance Abuse and Mental Health Services Administration. Current information on naltrexone and TIP 63: Medications for Opioid Use Disorder. TIP 63 reviews methadone, buprenorphine and naltrexone as FDA-approved medication approaches for OUD and describes antagonist induction, counselling and recovery support.
FDA
U.S. Food and Drug Administration. Current information on medications for opioid use disorder and prescribing information for extended-release injectable naltrexone. Key warnings include precipitated withdrawal, reduced opioid tolerance, potentially fatal overdose and the danger of attempting to overcome opioid blockade.
ASAM
American Society of Addiction Medicine. National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. Guidance addresses methadone, buprenorphine and naltrexone treatment selection and clinical management.
Cochrane 2025
Kornør H, Lobmaier PPK, Kunøe N. Sustained-release naltrexone for opioid dependence. Cochrane Database of Systematic Reviews. 2025;5:CD006140. The review included 22 randomized studies and 3,416 participants.
Implant vs Oral Naltrexone
Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Archives of General Psychiatry. 2009;66(10):1108–1115. PMID: 19805701.
Randomized Implant Trial
Krupitsky E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Archives of General Psychiatry. 2012.
Alcohol Use Disorder Evidence
McPheeters M, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023. The analysis included 118 trials and found evidence supporting oral naltrexone for clinically important alcohol outcomes.
Emerging Implant Research
Newer trials continue to investigate implant formulations, including recent alcohol-use-disorder research and early-phase longer-duration implant technologies. These remain product-specific findings and should not be generalized to all implants.
Evidence review updated for this page: September 2026. Regulatory status can change; patients and clinicians should confirm current information with the relevant regulator and the manufacturer of the exact product being considered.
Prepared for Medical Review by Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an educational evidence summary and is awaiting formal clinical approval. Until that process is completed, it should not be represented as having been medically reviewed.
View Dr Fergus Law’s professional profile
Review status: Pending clinical approvalEducational Information, Not Individual Medical Advice
This page is intended to help patients, families and healthcare professionals understand long-acting naltrexone and the questions that should be considered before treatment. It cannot determine whether naltrexone, an implant, an injection, oral medication, buprenorphine, methadone or another treatment is appropriate for a specific person.
Do not stop opioids, start naltrexone, alter prescribed addiction medication or attempt detoxification on the basis of this article alone. Urgent withdrawal, overdose, severe intoxication, breathing problems, loss of consciousness or other medical emergencies require immediate local medical assistance.